Varicella-Zoster Virus (Chickenpox) (2024)

Continuing Education Activity

Chickenpox or varicella is a contagious disease caused by the varicella-zoster virus. The virus is responsible for chickenpox (usually primary infection in nonimmune hosts) and herpes zoster or shingles (following reactivation of latent infection). Chickenpox results in a skin rash that forms small, itchy blisters that scab over. This activity describes the cause, presentation, and pathophysiology of chickenpox and highlights the interprofessional team's role in treating and preventing this infection.

Objectives:

Identify the etiology of chickenpox.
Evaluatethe presentation of chickenpox.
Determinethe treatment and management options available for chickenpox.
Communicateinterprofessional team strategies for improving care coordination and outcomes in patients with chickenpox.

Access free multiple choice questions on this topic.

Introduction

Chickenpox or varicella is a contagious disease caused by the varicella-zoster virus (VZV). The virus is responsible for chickenpox (usually primary infection in non-immune hosts) and herpeszoster or shingles(following reactivation of latent infection). Chickenpox results in a skin rash forming small, itchy blisters that scabs over. It typically starts on the chest, back, and face and then spreads. It is accompanied by fever, fatigue, pharyngitis, and headaches, usually lasting 5 to7 days. Complications include pneumonia, brain inflammation, and bacterial skin infections. The disease is more severe in adults than in children. Symptoms begin ten to 21 days after exposure, but the average incubation period is about2 weeks(see Image.Chickenpox [Varicella]).

Chickenpox is an airborne disease spread worldwide by coughing, sneezing, and contact with skin lesions. It may spread 1 to2 days before the rash appears until all lesions are crusted over. Patients with shingles may spread chickenpox to those who are not immune through blister contact. The disease is diagnosed based on the presenting symptoms and confirmed by polymerase chain reaction (PCR) testing of the blister fluid or scabs. Tests for antibodies may be performed to determine if immunity is present. Although reinfections by varicella may occur, these reinfections are usually asymptomatic and much milder than the primary infection.

The varicella vaccine was introduced in 1995 and has significantly decreased the number of cases and complications. It prevents about 70% to 90% ofinfections and 95% ofsevere disease. Routine immunization of children is recommended.Immunization within3 days of exposure may still improve outcomes in children.[1][2][3]

Etiology

Chickenpox or varicella is caused by the varicella-zoster virus (VZV), a herpes virus with worldwide distribution. It establishes latency after primary infection, a feature unique to most herpes viruses.[4]

Chickenpox is acquired by inhalation of infected aerosolized droplets. This virus is highly contagious and can spread rapidly. The initial infection is in the mucosa of the upper airways. The virus enters the circulation after 2 to 6 days, and another bout of viremia occurs in 10to 12 days. At this time, the characteristic vesicle appears. Immunoglobulin (Ig)A, IgM, and IgG antibodies are produced, but the IgG antibodies confer lifelong immunity. After the primary infection, varicella localized to sensory nerves and may reactivate later to produce shingles.

Epidemiology

Varicella occurs in all countries and is responsible annually for about 7000 deaths. In temperate countries, it is a common disease in children, with most cases occurring in winter and spring. In the UnitedStates, it accounts for more than 9000 hospitalizations annually. Its highest prevalence is in the 4- to 10-year-old age group. Varicella has an infection rate of 90%. Secondary cases in household contacts tend tohave more severe disease than primary cases. In the tropics, varicella tends to occur in older people and may cause more serious disease. Adults get deep pockmarks andmore prominent scars.[5][6][7]

Pathophysiology

Exposure causes the production of host IgG, IgM, and IgA. IgG antibodies persist for life and confer immunity. Cell-mediated immune responses are important in limiting the duration of primary varicella infection. After primary infection, varicella is theorized to spread to mucosal and epidermal lesions to local sensory nerves. It then remains latent in the dorsal ganglion cells of the sensory nerves. The immune system keeps the virus in check. However, reactivation can still occur later in life, resulting in the clinically distinct syndrome of herpes zoster (shingles), postherpetic neuralgia, and sometimes Ramsay Hunt syndrome type II. Varicella zoster can harm the arteries in the neck and head, resulting in a stroke.

The United States Advisory Committee on Immunization Practices (ACIP) suggests that all adults older than 60 should get vaccinated to avoid herpes zoster. One in5 adultswhohad chickenpox as children,especially those who are immune-suppressed, get singles. Shingles are most commonly found in adults over 60 diagnosed with chickenpox before age 1.[8][9]

History and Physical

The prodromal symptoms in adolescents and adults are aching muscles, nausea, decreased appetite, and headache, followed by a rash, oral sores, malaise, and a low-grade fever. Oral manifestations may precede the skin rash. In children, the illness may not bepreceded by prodromal symptoms, and the initial sign could be a rash or oral cavity lesions. The rash begins as small red dots on the face, scalp, torso, upper arms, and legs. Over the next ten to 12 hours, it progresses to small bumps, blisters, and pustules, and eventually, umbilication and scabs formation. Of note is that the rash of chickenpox occurs in crops and is typically at different stages of evolution.

Evaluation

The diagnosis of varicella infection is primarily based on the signs and symptoms. Confirmation is made by examination of the fluid within the vesicles, scraping of lesions that have not crusted, or by blood for evidence of an acute immunologic response. PCR has the highest yield and can be used for non-skin samples such as bronchoalveolar lavage and cerebrospinal fluid. Direct fluorescent antibody testing has largely replaced the Tzanck test. The vesicular fluid can also be cultured,but the yield is low compared to PCR. Blood tests identify a response to acute infection (IgM), previous infection, and subsequent immunity (IgG). Prenatal diagnosis of fetal varicella can be performed using ultrasound, though a delay of 5 weeks following primary maternal infection is advised. A PCR (DNA) test of the amniotic fluid can be performed. However, the risk of spontaneous abortion due to amniocentesis is higher than the risk of the baby developing fetal varicella.[10][11]

Treatment / Management

Treatment is symptomatic relief of symptoms. As a protective measure, those infected are usually required to stay home while infectious. Keeping nails short and wearing gloves may prevent scratching and reduce the risk of secondary infections.[12][13][1]

Topical calamine lotion may relieve pruritus. Daily cleansing with warm water helps avoid secondary bacterial infection. Acetaminophen may be used to reduce fever. Avoid aspirin as it may cause Reye syndrome. People at risk of developing complications and who have had significant exposure may be given intramuscular varicella-zoster immune globulin, a preparation containing high titers of antibodies to the varicella-zoster virus, to help prevent the disease.[14]

In children: Acyclovir decreases symptoms by1 day if taken within 24 hours of the start of the rash. Still, it does not affect complication rates and is not recommended for individuals with normal immune function.
In adults,infection tends to be more severe, and treatment with antiviral drugs (acyclovir or valacyclovir) is advised if they can be started within 24 to 48 hours of rash onset. Supportive care, such as increasing water intake and using antipyretics and antihistamines, is important to management. Antivirals are typically indicated in adults, including pregnant women, because this group is more prone to complications. The preferred treatmentis usuallyoral therapy, but intravenous antivirals are indicated for immunocompromised patients.

The varicella-zoster immunoglobulin is used to manage immunocompromised patients. In addition, a live attenuated vaccine has been available since 1995. There is high seroconversion following the vaccine, which is long-lasting. Adverse effects of the vaccine are rare.

Differential Diagnosis

The differential diagnoses forchickenpox include the following:

Insect bites
Impetigo
Smallpox
Drug eruptions
Dermatitis herpetiformis

Prognosis

The prognosis is excellent in healthy children. However, the infection has high morbidity in immunocompromised individuals.

Consultations

Consultations that are typically requested for patients with this condition include the following:

Pearls and Other Issues

Chickenpox is rarely fatal. Nonimmune pregnant women and those immunocompromised are at highest risk. Arterial ischemic stroke associated with childhood chickenpox is a significant risk. Varicella pneumonia is the most common cause of fatality in adults (10% to30%), and in those requiring mechanical ventilation, this may reach 50%.

In pregnant women, antibodies from immunization or previous infection are transferred via the placenta to the fetus. Varicella infection in pregnant women could spread via the placenta and infect the fetus. If infection occurs during the first 28 weeks of pregnancy, congenitalvaricella syndrome may develop. Effects on the fetus can includeunderdeveloped toes and fingers, structural eye damage, neurological disorder, and anal and bladder malformation.

If maternal infection occurs7 days before delivery and up to8 days following birth, the baby may develop neonatal varicella with presentation ranging from mild rash to disseminated infection. Newborns who develop symptoms are at a high risk of pneumonia and other serious complications. Maternal herpes zoster, on the other hand, constituteslittle risk of neonatal complications or congenital varicella syndrome, probably because of established circulating maternal antibodies.

Enhancing Healthcare Team Outcomes

Chickenpox is usually acquired after inhalation of aerosolized droplets froman infected individual. The majority of cases occur in children less than 10. The key to lowering the morbidity of chickenpox is education. Besides the primary caregiver, the nurse practitioner and pharmacist are vital in patient education. The parents of infected childrenshould be told to trim the child's fingernails to avoid or minimize skin damage and associated bacterial infections. Further, parents should be told not to give aspirin to young children to control fever because of the risk of developing Reye syndrome. Finally, the parents should be told to apply cold compresses and moisturize the skin to prevent itching and dryness.[15][16][17] All clinicians should urge parents to get their children vaccinated because this can prevent the morbidity associated with the infection. The vaccine is safe and very effective. Immunocompromised children should be referred to an infectious disease specialist for further management. (Level V) Clinicians should also educate pregnant women who are seronegative for chickenpox to avoid contact with patients with an active infection. All pregnant women who develop chickenpox must be managed by a team of specialists who can make a treatment decision.

Outcomes

For most children who develop chickenpox, the outcome is excellent. However, in immunocompromised individuals, there is increased morbidity and mortality.[18][19][20]

Review Questions

Figure

Chickenpox (Varicella). Chickenpox is seen in an unvaccinated child. Public Health Image Library, Public Domain, Centers for Disease Control and Prevention

References

1.: Shrim A, Koren G, Yudin MH, Farine D. No. 274-Management of Varicella Infection (Chickenpox) in Pregnancy. J Obstet Gynaecol Can. 2018 Aug;40(8):e652-e657. [PubMed: 30103889]
2.: Pereira L. Congenital Viral Infection: Traversing the Uterine-Placental Interface. Annu Rev Virol. 2018 Sep 29;5(1):273-299. [PubMed: 30048217]
3.: Kasabwala K, Wise GJ. Varicella-zoster virus and urologic practice: a case-based review. Can J Urol. 2018 Jun;25(3):9301-9306. [PubMed: 29900816]
4.: Al-Turab M, Chehadeh W. Varicella infection in the Middle East: Prevalence, complications, and vaccination. J Res Med Sci. 2018;23:19. [PMC free article: PMC5961286] [PubMed: 29887897]
5.: Rice ME, Bannerman M, Marin M, Lopez AS, Lewis MM, Stamatakis CE, Regan JJ. Maritime varicella illness and death reporting, U.S., 2010-2015. Travel Med Infect Dis. 2018 May-Jun;23:27-33. [PMC free article: PMC6624850] [PubMed: 29621623]
6.: Schmader K. Herpes Zoster. Clin Geriatr Med. 2016 Aug;32(3):539-53. [PubMed: 27394022]
7.: Bakker KM, Martinez-Bakker ME, Helm B, Stevenson TJ. Digital epidemiology reveals global childhood disease seasonality and the effects of immunization. Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):6689-94. [PMC free article: PMC4914188] [PubMed: 27247405]
8.: Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018 Apr;41(2):95-105. [PubMed: 29498740]
9.: Dayan RR, Peleg R. Herpes zoster - typical and atypical presentations. Postgrad Med. 2017 Aug;129(6):567-571. [PubMed: 28540752]
10.: Inata K, Miyazaki D, Uotani R, Shimizu D, Miyake A, Shimizu Y, Inoue Y. Effectiveness of real-time PCR for diagnosis and prognosis of varicella-zoster virus keratitis. Jpn J Ophthalmol. 2018 Jul;62(4):425-431. [PubMed: 29948430]
11.: Onyango CO, Loparev V, Lidechi S, Bhullar V, Schmid DS, Radford K, Lo MK, Rota P, Johnson BW, Munoz J, Oneko M, Burton D, Black CM, Neatherlin J, Montgomery JM, Fields B. Evaluation of a TaqMan Array Card for Detection of Central Nervous System Infections. J Clin Microbiol. 2017 Jul;55(7):2035-2044. [PMC free article: PMC5483905] [PubMed: 28404679]
12.: Harrington D, Haque T. Varicella Zoster Immunoglobulin G (VZIG)-Do current guidelines advocate overuse? J Clin Virol. 2018 Jun;103:25-26. [PubMed: 29609167]
13.: Poole CL, James SH. Antiviral Therapies for Herpesviruses: Current Agents and New Directions. Clin Ther. 2018 Aug;40(8):1282-1298. [PMC free article: PMC7728158] [PubMed: 30104016]
14.: Hayward K, Cline A, Stephens A, Street L. Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol. 2018 Oct;38(7):887-894. [PubMed: 29565203]
15.: Ogunjimi B, Van den Bergh J, Meysman P, Heynderickx S, Bergs K, Jansens H, Leuridan E, Vorsters A, Goossens H, Laukens K, Cools N, Van Tendeloo V, Hens N, Van Damme P, Smits E, Beutels P. Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox. Sci Rep. 2017 Apr 24;7(1):1077. [PMC free article: PMC5430877] [PubMed: 28439065]
16.: Ogunjimi B, Van Damme P, Beutels P. Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. PLoS One. 2013;8(6):e66485. [PMC free article: PMC3689818] [PubMed: 23805224]
17.: Meylan P, Gerber S, Kempf W, Nadal D., Swiss Herpes Management Forum. [Swiss recommendations for the management of varicella-zoster virus infections]. Rev Med Suisse. 2007 Sep 19;3(125):2116-22, 2124-9. [PubMed: 17939531]
18.: Wang X, Zhang X, Yu Z, Zhang Q, Huang D, Yu S. Long-term outcomes of varicella zoster virus infection-related myelitis in 10 immunocompetent patients. J Neuroimmunol. 2018 Aug 15;321:36-40. [PubMed: 29957386]
19.: McRae JE, Quinn HE, Macartney K. Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2015: Prospective hospital-based surveillance for serious paediatric conditions. Commun Dis Intell Q Rep. 2017 Sep 01;41(3):E264-E278. [PubMed: 29720076]
20.: Dommasch ED, Joyce CJ, Mostaghimi A. Trends in Nationwide Herpes Zoster Emergency Department Utilization From 2006 to 2013. JAMA Dermatol. 2017 Sep 01;153(9):874-881. [PMC free article: PMC5710426] [PubMed: 28636704]

: Disclosure: Folusakin Ayoade declares no relevant financial relationships with ineligible companies.
: Disclosure: Sandeep Kumar declares no relevant financial relationships with ineligible companies.